CTI BioPharma to Present at the JMP Securities Hematology and Oncology Summit

Rhea-AI Summary

CTI BioPharma Corp. (NASDAQ: CTIC) will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit on December 6, 2022, at 3:00 p.m. ET. This event will be held virtually and can be accessed via webcast on CTI BioPharma's website. The company focuses on developing targeted therapies for blood-related cancers, including its FDA-approved product, VONJO®, for myelofibrosis treatment. Continued approval for VONJO is contingent upon outcomes from confirmatory trials.

News Market Reaction – CTIC

+4.15%

1 alert

+4.15% News Effect

On the day this news was published, CTIC gained 4.15%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

SEATTLE, Nov. 30, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit at 3:00 p.m. ET. The conference will be held in a virtual meeting format.

Presentation details:

Event: JMP Securities Hematology and Oncology Summit
Date: Tuesday, December 6, 2022
Time: 3:00 p.m. ET

The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma's website at www.ctibiopharma.com.

About CTI BioPharma Corp.
We are a commercial biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product, VONJO^® (pacritinib), a JAK2 and IRAK1 inhibitor, that spares JAK1. VONJO is approved for the treatment of adults with intermediate- or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10⁹/L. This indication is approved under FDA accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement.

VONJO^® is a registered trademark of CTI BioPharma Corp.

CTI BioPharma Investor Contacts:
Argot Partners
+212-600-1902
cti@argotpartners.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/cti-biopharma-to-present-at-the-jmp-securities-hematology-and-oncology-summit-301689490.html

SOURCE CTI BioPharma Corp.

FAQ

What is CTI BioPharma's participation in the JMP Securities Summit?

CTI BioPharma will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit on December 6, 2022, at 3:00 p.m. ET.

Where can I watch CTI BioPharma's presentation?

CTI BioPharma's presentation will be webcast live and available for replay on their website at www.ctibiopharma.com.

What is VONJO and its approved indication?

VONJO^® is an FDA-approved treatment for adults with myelofibrosis and severe thrombocytopenia, specifically for those with a platelet count below 50 × 10⁹/L.

What is the significance of the PACIFICA study?

The PACIFICA study is a Phase 3 clinical trial for VONJO, required for verifying clinical benefit as part of the post-marketing approval process.

What date and time is the event where CTI BioPharma will speak?

The event is scheduled for December 6, 2022, at 3:00 p.m. ET.